Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Invion ( (AU:IVX) ).
At its 2025 Annual General Meeting, Invion Limited successfully passed several resolutions, including the adoption of a remuneration report, re-election of a director, and approval of share and option plans. These resolutions are expected to strengthen Invion’s operational framework and support its strategic initiatives in advancing its Photosoft™ technology, thereby enhancing its position in the life-science industry.
More about Invion
Invion is a life-science company focused on the research and development of Photosoft™ technology, a novel form of Photodynamic Therapy (PDT) for treating cancers, atherosclerosis, and infectious diseases. The company holds exclusive rights to this technology in various regions including Australia, New Zealand, and parts of Asia and Oceania. Invion is listed on the ASX and collaborates with RMW Cho Group Limited for funding research and clinical trials.
YTD Price Performance: -71.79%
Average Trading Volume: 76,662
Technical Sentiment Signal: Sell
Current Market Cap: A$6.77M
For an in-depth examination of IVX stock, go to TipRanks’ Overview page.